Latest Medicare Data Suggests No Heightened Death Risk For Paclitaxel-Coated Devices
Executive Summary
A large study of US Medicare patients treated with either drug-coated stents, balloons or other equivalent devices shows a similar morbidity rate in both groups, further contradicting a 2018 literature review that warned of higher death rates in patients treated with paclitaxel-coated devices.
You may also be interested in...
FDA-Guided Study Finds No Paclitaxel Death Risk In Medicare Patients
The SAFE-PAD study, which looked at data from more than 168,000 Medicare beneficiaries, found a slightly lower death rate in patients treated with drug-coated balloons and stents than those who were not.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.